-
Mashup Score: 1Miguel Perales (@drmiguelperales) on Threads - 11 month(s) ago
Chief, Adult BMT Service @memorialsloankettering President @ASTCT. 34 Followers.
Source: ThreadsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0In conversation with... - 11 month(s) ago
Editors of The Lancet OncologyĀ and the journalās authors explore their research and its impact on peopleās health, health care, and health policy in this regular podcast.
Source: BuzzsproutCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW: Senior Editor Owen Stretton talks to Carlos FernĆ”ndez de Larrea (Hospital ClĆnic de Barcelona) and Damian Green (Fred Hutch Cancer Center) about their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma. #tcellrx #mmsm https://t.co/PUBeg5qnP9
-
-
Mashup Score: 0The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies - 11 month(s) ago
Section snippetsKey pointsā¢Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have led to significant advancements in the management of relapsed/refractory blood cancers with several FDA approved products for multiple myeloma, non-Hodgkin lymphoma and B-cell lymphoblastic leukemia.ā¢In the absence of head-to-head comparisons of CAR T-cell therapy versus bispecific antibodies,…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bis... https://t.co/pazRLv2zXB #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy
-
-
Mashup Score: 5
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) ā – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT ā
Source: CRISPR TherapeuticsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA Accepts Biologics License Applications for exa-cel) for Severe SCD and Transfusion-Dependent Beta Tha| CRISPR Therapeutics #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT ā¦@CARTTherapyā© https://t.co/fn98bS8Jkg
-
-
Mashup Score: 0
Manali Kamdar, MD, University of Colorado, Aurora, CO, gives an overview of treatment options available for patients with primary refractory…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We had a lovely interview with Manali Kamdar (@mana1981) of @CUBoulder, who discussed therapeutic options for patients with primary refractory/early relapsed DLBCL: š„ https://t.co/PCmP09t0Xr @ASCO #LymSM #DLBCL #HemOnc #ImmunoOnc #CARTcell #tcellrx #ASCO23 #CIM23
-
-
Mashup Score: 3
Abstract RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are autologous stem cell transplant ineligible. We present outcomes data for three pre-specified treatments not assessed in the primary analysis. Data…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituxiā¦ https://t.co/wn2xycuHK0 #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy https://t.co/Acq3TpVJhT
-
-
Mashup Score: 3Overcoming R/R myeloma with T-cell engaging therapies - 1 year(s) ago
VJHemOnc is excited to bring you highlights from the 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 with leading experts discussing the latest on T-cell engaging immunotherapies.
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
š£ Check out our latest article about T-cell engagers in #MultipleMyeloma. ā”ļø Learn about the latest updates on teclistamab, elranatamab, ide-cel, cilta-cel & GPRC5D TCEs. šhttps://t.co/2KeXk64gKX #HemOnc #Myeloma #MMsm #ImmunoOnc #tcellrx #CART
-
-
Mashup Score: 0Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory largeĀ B-cell lymphoma - 1 year(s) ago
Key Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory LBCL.Durable responses were associated wit
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory largeĀ B-cell lymphoma #tcellrx #CellTherapy #lymsm @BloodJournal https://t.co/CuZlYI9UlX
-
-
Mashup Score: 2
Key Points. Chronic stimulation of CD28-based CARs drives T cells to become exhausted, while 41BB-based CARs direct a novel state of T cell dysfunction41BB-driv
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @BloodAdvances https://t.co/UH80b9NkR9
-
-
Mashup Score: 2Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma - 1 year(s) ago
Key Points. MTV and ctDNA did not correlate in patients with LBCL with evidence of disease 1 month post axi-cel, suggesting ongoing therapy response.MTV and ctD
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma https://t.co/hfUfBlpNkG #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @BloodAdvances
-
Who else is moving to š§µ follow me there for the usual content #bmtsm #cartcells #tcellrx https://t.co/ppnB8EaTfn https://t.co/KkRE4V3KfD